BioRestorative Therapies, Inc. closed a public offering, raising $5.0 million through the sale of 14,285,715 shares of common stock. The company will use the net proceeds for clinical trials, research and development, and general corporate purposes. The offering was facilitated by Rodman & Renshaw LLC, with warrants exercisable at $0.35 per share. BioRestorative develops regenerative therapies using adult stem cells, focusing on disc/spine diseases and metabolic disorders. Their BioCosmeceutical platform offers cell-based products for cosmetic use, with plans to expand into biologic aesthetic therapies. The company operates in compliance with FDA regulations.

Read more at GlobeNewswire: BioRestorative Announces Closing of $5.0 Million Public